Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Lutterotti, A; Kuenz, B; Gredler, V; Khalil, M; Ehling, R; Gneiss, C; Egg, R; Deisenhammer, F; Berger, T; Reindl, M.
Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
J Neuroimmunol. 2006; 181(1-2):145-149
Doi: 10.1016/j.jneuroim.2006.09.002
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Khalil Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The aim of this study was to evaluate a possible role of soluble CD14 (sCD14) in multiple sclerosis (MS). We found that sCD14 serum levels measured by ELISA were higher in MS patients compared to neurological and healthy controls. Within the MS group sCD14 levels were increased in relapsing-remitting and secondary progressive MS compared to primary progressive MS. Furthermore, sCD14 concentrations were increased during stable disease. An increased expression of sCD14 was also detected after treatment with interferon-beta. In summary, we report evidence that serum sCD14 levels are increased in MS and correlate inversely with disease activity in relapsing MS patients.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Antigens, CD14 - blood
- Biological Response Modifiers - therapeutic use
- Enzyme-Linked Immunosorbent Assay - therapeutic use
- Female - therapeutic use
- Humans - therapeutic use
- Interferon-beta - therapeutic use
- Male - therapeutic use
- Middle Aged - therapeutic use
- Multiple Sclerosis, Chronic Progressive - blood
- Multiple Sclerosis, Relapsing-Remitting - blood
- Severity of Illness Index - blood
- Solubility - blood
- Find related publications in this database (Keywords)
- multiple sclerosis
- soluble CD14
- disease activity
- innate immunity